Topical Tranexamic Acid in Complex Cardiac Surgery: Does it Reduce Transfusion Need?


About this study

The goal of ths study is to determine the effectiveness of adding topical tranexamic acid (TXA) to our standard practice of care for patients undergoing redo or complex cardiac procedures. The study will use a control group for comparision.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria: 

  • Patients undergoing complex cardiac surgery (redo operations, combined operations such as CABG + valve, multiple valve).
  • Male or female.
  • Patients > 18 years of age.

Exclusion Criteria:

  • Patients < 18 years of age.
  • Patients with allergy to TXA.
  • Patients with prior history of thrombosis.
  • Patients who cannot grant informed consent.
  • Patients with coagulopathic conditions such as factor deficiencies, factor inhibitors, heparin induced thrombocytopenia, or use of intravenous anticoagulants other than heparin at the time of cardiovascular surgery.
  • Patients who have received oral therapy with clopidogrel, prasugrel, rivaroxaban or dabigatran within the past 3 days.
  • Patients who are taking chronic warfarin therapy who have not discontinued treatment and demonstrated an INRgreater than 1.5 prior to surgery.
  • Patients who are undergoing emergency open heart-surgery.
  • Patients for whom procedures for which the cardiopulmonary bypass time is expected to be < 30 minutes.
  • Patients for whom procedures for which the cardiopulmonary bypass is excepted to not be normothermic (temperature ≥ 35 degrees C).
  • Patients who cannot receive heparin.
  • Pregnant patients.


Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Hartzell Schaff, M.D.

Open for enrollment

Contact information:

Sameh Said M.D., M.B.

(507) 255-9206

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available